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1132However, the distinction between calciﬁed spots
and metallic markers with computed tomography
is also not easy to determine compared with OCT.
The possible advantages of OCT are the ability to:
1) distinguish the MRMs from underlying calcium
more clearly than MSCT; 2) measure the embedment
of the struts; and 3) evaluate the thickness of neo-
intima because of a higher axial resolution of around
10 to 15 mm as compared with MSCT.
The limitation in this study is that the study result
was able to conﬁrm the persistent presence of MRMs
only at medium-term follow-up, and the long-term
results still require investigation.
In conclusion, MRM recognition by MSCT is critical
for precise noninvasive assessment of the coronary
location of all MRMs. On the basis of our study criteria,
there was no evidence of MRMs dislodgement and
embolization 18 months after scaffold implantation.Pannipa Suwannasom, MD
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3-Year Follow-Up of the
Balloon Elution and Late
Loss Optimization Study
(BELLO)
The optimal treatment of de novo small-vessel coro-
nary artery disease remains unclear. The use of drug-
eluting stents in this patient group are limited by
high rates of restenosis (1) and the requirement of
prolonged treatment with dual antiplatelet therapy.
The use of drug-coated balloons (DCB) might be an
alternative treatment option. There are currently
limited data with regard to the long-term efﬁcacy of
this strategy (2), and currently no randomized data
to support this approach. The BELLO (Balloon
Elution and Late Loss Optimization) study (3) was
an investigator-initiated, prospective, multicenter,
single-blinded, active-treatment controlled cli-
nical trial. In BELLO, 182 patients undergoing percu-
taneous revascularization of small coronary vessels
(reference vessel diameter <2.8 mm by visual esti-
mation) were randomly assigned in a 1:1 ratio to
treatments with: 1) In.Pact Falcon paclitaxel DCB
(Medtronic, Inc., Santa Rosa, California) dilation and
provisional bare-metal stenting; or 2) paclitaxel-
eluting stent (PES) (Taxus Liberté, Boston Scientiﬁc,
Marlborough, Massachusetts) implantation as per
standard clinical practice. We have shown that
treatment of small-vessel disease with a paclitaxel
DCB is associated with less angiographic late loss and
similar rates of restenosis and revascularization as
PES is at 1 year. Here we report the ﬁnal pre-deﬁned,
protocol-mandated 3-year clinical follow-up results
of this study population.
A total of 182 patients were enrolled at 15 Italian
centers and randomized to treatment with DCB
(n ¼ 90) in 94 lesions or PES (n ¼ 92) in 98 lesions.
Patients were eligible if $18 years of age, with a
diagnosis of stable or unstable angina or documented
ischemia and a maximum of 2 angiographically sig-
niﬁcant de novo lesions <25 mm in length in native
coronary arteries with a visually estimated reference
FIGURE 1 3-Year Outcomes Following DCB Treatment for De Novo Coronary Disease in Small Vessels in Comparison With PES Treatment
There was a statistically signiﬁcant beneﬁt in the drug-coated balloon (DCB) group in comparison with the paclitaxel-eluting stent (PES) group with regard to 3-year
composite major adverse cardiac events (MACE) (p ¼ 0.015) (A). There were no differences between groups with regard to target vessel revascularization (TVR)
(p ¼ 0.32) (B) and target lesion revascularization (TLR) (p ¼ 0.14) (C).
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1133vessel diameter of <2.8 mm. Exclusion criteria and
baseline characteristics of patients included in the
study have been previously published (3). Of note,
there was a high incidence of diabetes mellitus (43.3%
in DCB and 38% in PES) and the majority of lesions
treated were in vessels <2.5 mm (89.4% vs. 87.8%).
The primary endpoint was angiographic in-stent
(or in-balloon) late lumen loss at follow-up angio-
graphy at 6 months. Secondary endpoints included
the occurrence of major adverse cardiac events
(MACE), deﬁned as the composite of all-cause
death, myocardial infarction, and target vessel
revascularization.
A total of 173 patients (95.1%) were included in the
ﬁnal analysis: 166 patients completed 3-year follow-
up (83 patients in each group) and 7 patients died: 2
patients in the DCB group (1 sudden cardiac death,
1 following coronary artery bypass graft surgery) and
5 patients in the PES group (3 cancer, 1 respiratory
failure, 1 following stroke). Nine patients (4.9%) were
lost to follow-up.
The occurrence of the ﬁrst event of the MACE
composite up to 1,100 days was analyzed using the
Kaplan-Meier method and showed a statistically sig-
niﬁcant difference between groups (DCB group: n ¼ 13
[14.4%], and PES group: n ¼ 28 [30.4%], p ¼ 0.015)
(Figure 1A). Three patients (3.3%) underwent target
vessel revascularization in the DCB group and 6 pa-
tients (6.5%) in the PES group (p ¼ 0.32) (Figure 1B).
Six patients (6.7%) underwent target lesion revascu-
larization in the DCB group and 12 patients (13%) in
the PES group (p ¼ 0.14) (Figure 1C). There were no
reported instances of target stent (or vessel) throm-
bosis in either group.
In the subgroup of 75 patients with diabetes mel-
litus, 65 patients completed 3-year follow-up (DCB
group: n ¼ 35; PES group: n ¼ 30), 6 patients died and4 were lost to follow-up. At least 1 MACE occurred in
6 patients (15.4%) in the DCB group and in 14 patients
(38.9%) in the PES group, favoring treatment with
DCB (p ¼ 0.02). There were no differences between
groups with regard to target vessel revascularization
(DCB group: n ¼ 1; PES group: n ¼ 2; p ¼ 0.51) or target
lesion revascularization (DCB group: n ¼ 2; PES group:
n ¼ 6; p ¼ 0.11).
The use of DCB is attractive in the management of
de novo coronary disease because it does not require
prolonged dual antiplatelet therapy and can be used
where vessels are too small to allow for optimal stent
implantation. For the treatment of novo disease,
a recent meta-analysis concluded DCB use was non-
inferior to both bare-metal stents and PES (4) and
efﬁcacywas further demonstrated in a prospective “all-
comer” registry that demonstrated a low MACE and
target lesion revascularization rate with DCB use (5).
Data from this extended follow-up suggest the
treatment of small vessels with DCB has good efﬁ-
cacy compared with PES treatment at 3-year follow-
up in support of our observation at 1 year (3).
Interestingly, there was a statistically signiﬁcant
beneﬁt with regard to MACE at 3 years with DCB
when compared with PES. Whereas this study was
not adequately powered for this endpoint, it does
raise the interesting hypothesis that treatment of
small vessels with DCB might be associated with an
outcome beneﬁt.
In conclusion, the use of DCB in the treatment of de
novo coronary lesions in small vessels appears to be
an efﬁcacious strategy when compared with PES
treatment at 3 years. This holds true in high-risk
diabetic patients. Further larger studies are required
to evaluate whether there is an additional outcome
beneﬁt associated with this approach, especially with
new generation limus-eluting stents.
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Risk Adjusted Mortality
Ratings and Public
Reporting for High-Risk PCIWe appreciate the perspective of the comments by Drs.
Miner andNield (1) regarding our study (2). As noted byDrs. Miner and Nield (1), there are many limitations to
any form of observational risk-adjusted outcomes
comparisons. Certainly cardiac arrest or shock patients
have a gradient of risk, and certainly providers may
have a gradient in who they take to the lab or how they
classify and report “high risk.” In individual cases, a
provider could overcall shock in a lower-risk case and
thereby have better observed results than expected.
However, the American College of Cardiology–NCDR
(National Cardiovascular Data Registry) risk models
were developed from real-world data. As such,
provider-related factors would have already been
incorporated into the models. Thus, such variation in
community practice is unlikely to explain why, in
aggregate, providers who take on more high-risk cases
do better. More importantly, in our analyses of the
“concentrated risk year,” we used the individual pro-
viders themselves as their own control group. We
found in such high-risk scenarios, providers’ “risk-
adjusted” outcome performance was as good or better
in high-risk cases than when the provider faced
normal-risk or low-risk groups. So, we believe our
paper provides compelling evidence that, in aggre-
gate, the NCDR percutaneous coronary intervention
risk models adequately assess and compensate pro-
viders for taking high-risk cases to the lab.
However, Miner and Nield (1) also raise an impor-
tant point regarding whether or not public reporting
itself is harmful or helpful. To be clear, our paper
should not be seen as an endorsement of public
reporting, and we agree the assessment of the total
impact of public reporting is complex. On the one
hand, public reporting does provide consumers with
information on provider outcomes as well as give
providers an incentive to monitor and hopefully
improve their procedural outcomes. Although there is
much debate whether consumer choice is improved
via public reporting, there has been consistent evi-
dence supporting the value of performance mea-
surement and subsequent provider-led quality
improvement, including door-to-balloon times, as
well as with the outcomes of acute myocardial
infarction, heart failure (3), and stroke (4). On the
other hand, public outcome reporting could make
certain providers “gun shy” and unwilling to take
high-risk cases to the lab, even in situations where
revascularization may be beneﬁcial (such as ST-
segment elevation myocardial infarction or shock).
Previous studies have indicated that states with
public reporting use PCI less and perhaps have worse
outcomes than do states without (5). However, these
studies were the exact motivation for our paper. Risk-
averse clinician behavior likely represents the pro-
vider’s fear that taking on high-risk cases will “hurt”
